Project Grant R01HL184037
Award Date 8/4/26
Completion Date 4/30/31
Dollars Obligated $735K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35233, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $317,484 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 25, 2025. This is a K01 Project Grant (K01HL171839), a research career development award supporting early-stage investigators. The research develops genotypic and phenotypic approaches to subtype individuals with coronary heart disease. The recipient will identify novel genetic variants associated with incident...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $222,750 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 21, 2025, with a completion date of June 30, 2027. The grant supports the development of a clinical decision support questionnaire designed to identify barriers to blood pressure control among adults with hypertension. This tool addresses a critical gap in...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $713,515 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate the neural mechanisms linking meal timing, circadian rhythms, and blood pressure control in diet-induced obesity. The project, titled "Food Intake Timing on Circadian Control of Blood Pressure in Diet-Induced Obesity," seeks to elucidate how the suprachiasmatic nucleus and...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $735,327 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine individual and contextual risk factors for chronic limb-threatening ischemia (CLTI) and contributors to racial and geographic disparities in CLTI outcomes. The award funds research leveraging the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study, a longitudinal cohort of...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $1,491,464 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, for Project Grant R01HL178770, a research study comparing ambulatory blood pressure monitoring (ABPM) to wrist-worn home blood pressure monitoring (HBPM) in assessing end-organ damage. The study, titled AW-COMPARE, will evaluate whether wrist-worn HBPM devices can replace ABPM as the reference standard for...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $754,413 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a randomized controlled trial of remote blood pressure monitoring, pharmacist-led telehealth medication management, and automated text reminders integrated into an emergency department transitional care clinic model for hypertensive patients. The trial, titled REMAP-BP (Remote Blood Pressure...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $222,750 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how innate lymphoid cell memory formed during neonatal lung injury contributes to chronic obstructive pulmonary disease development in adulthood. The project, titled "Trained Immunity in Group 2 Innate Lymphoid Cells Links Neonatal to Adult Chronic Lung...
- <p>The National Institutes of Health National Heart Lung and Blood Institute awarded the University of Alabama at Birmingham $223,500 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt telecommunicator CPR instructions to enhance layperson response to pediatric cardiac arrest. The award is a Project Grant (R03HL185261) with a period of performance through May 31, 2028, and work is performed in Birmingham, Alabama.</p>
- Federal Grant Award Summary The University of Alabama at Birmingham received a $222,750 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through July 31, 2027. The research deliverables focus on identifying immunogenetic risk factors associated with chronic obstructive pulmonary disease (COPD) exacerbations in African American populations. Specifically, the project...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $1,254,849 on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop engineered small extracellular vesicles for treating diabetic ischemic heart failure. The research addresses the mechanism by which type 2 diabetes confers treatment resistance in ischemic heart failure, focusing on downregulation of CTRP9, a cardioprotective cardiokine that impairs small...